GlassScriptPhysician profile
Michael Terrence Collins
NPI 1336382712
$91,548.23
in general payments reported to CMS, 2019-2025
6 companies · $82K in 2025
The $82K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,288 · 2023: $198 · 2024: $2,652 · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $84K · Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $84,257.50 |
| Food and Beverage | $1,002.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $82,139.73 | 2024-2025 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $6,162.74 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $2,580.50 | 2019-2024 | |
| Kyowa Kirin, INC. | $263.56 | 2024-2025 | |
| Amgen INC. | $213.70 | 2024-2025 | Evenity |
| Pharmacosmos Therapeutics INC. | $188.00 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.